Table 4.

Univariate analysis of KRAS mutations’ evolution prognostic power.

KRAS evolution	No. ofevents/patients	Median survival	95% CI	P at Log Rank test
Mut in PT → Mut in MT	20/53	9.6	6.7–16.4
Mut in PT → WT in MT	4/10	NR	21.1–33.6
WT in PT → WT in MT	15/27	27.5	22.8–29.8
WT in PT → Mut in MT	11/24	12.1	9.6–15.9	0.0001

CI, Confidence Interval; MT, Metastatic Tumors; Mut, KRAS mutated; NR, Not Reached; PT, Primary Tumors; WT, Wild-Type.